Key Details
Annual ROE
-1187.40%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 09, 2022Recent annual earnings:
Feb 25, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
13 Sept '22 Guggenheim
Neutral09 Sept '22 Morgan Stanley
Equal-Weight09 Aug '22 SVB Leerink
Market Perform11 May '22 Morgan Stanley
Equal-Weight11 May '22 HC Wainwright & Co.
Buy10 May '22 SVB Leerink
Market Perform11 Apr '22 SVB Leerink
Market Perform11 Apr '22 Morgan Stanley
Equal-Weight11 Apr '22 HC Wainwright & Co.
Buy11 Apr '22 Guggenheim
BuyScreeners with RUBY included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Rubius Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
RUBY
globenewswire.com14 June 2024
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
FAQ
- What is the primary business of Rubius Therapeutics?
- What is the ticker symbol for Rubius Therapeutics?
- Does Rubius Therapeutics pay dividends?
- What sector is Rubius Therapeutics in?
- What industry is Rubius Therapeutics in?
- What country is Rubius Therapeutics based in?
- When did Rubius Therapeutics go public?
- Is Rubius Therapeutics in the S&P 500?
- Is Rubius Therapeutics in the NASDAQ 100?
- Is Rubius Therapeutics in the Dow Jones?
- When was Rubius Therapeutics's last earnings report?
- When does Rubius Therapeutics report earnings?
- Should I buy Rubius Therapeutics stock now?
What is the primary business of Rubius Therapeutics?
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
What is the ticker symbol for Rubius Therapeutics?
The ticker symbol for Rubius Therapeutics is NASDAQ:RUBY
Does Rubius Therapeutics pay dividends?
No, Rubius Therapeutics does not pay dividends
What sector is Rubius Therapeutics in?
Rubius Therapeutics is in the Healthcare sector
What industry is Rubius Therapeutics in?
Rubius Therapeutics is in the Biotechnology industry
What country is Rubius Therapeutics based in?
Rubius Therapeutics is headquartered in United States
When did Rubius Therapeutics go public?
Rubius Therapeutics's initial public offering (IPO) was on 18 July 2018
Is Rubius Therapeutics in the S&P 500?
No, Rubius Therapeutics is not included in the S&P 500 index
Is Rubius Therapeutics in the NASDAQ 100?
No, Rubius Therapeutics is not included in the NASDAQ 100 index
Is Rubius Therapeutics in the Dow Jones?
No, Rubius Therapeutics is not included in the Dow Jones index
When was Rubius Therapeutics's last earnings report?
Rubius Therapeutics's most recent earnings report was on 9 November 2022
When does Rubius Therapeutics report earnings?
The date for Rubius Therapeutics's next earnings report has not been announced yet
Should I buy Rubius Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions